Adherence to treatment of chronic hepatitis C
Open Access
- 1 July 2016
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medicine
- Vol. 95 (28), e4151
- https://doi.org/10.1097/md.0000000000004151
Abstract
Patients' experience during treatment may affect treatment adherence. Our aim was to assess the impact of patient-reported outcomes (PROs) on adherence to different anti-hepatitis C virus (HCV) regimens.Clinical, demographic, and PRO data (short form-36 [SF-36], chronic liver disease questionnaire-hepatitis C version [CLDQ-HCV], functional assessment of chronic illness therapy-fatigue [FACIT-F], work productivity and activity impairment: specific health problem [WPAI:SHP]) from 13 multinational clinical trials of anti-HCV treatment were available. Treatment adherence was defined as >80% of prescribed doses taken.Included were 4825 HCV patients. Regimens were grouped into: interferon- and ribavirin (RBV)-containing (±sofosbuvir [SOF]), interferon-free RBV-containing (RBV + SOF ± ledipasvir [LDV]), and interferon-free RBV-free (LDV/SOF). The adherence to these regimens were 77.6%, 84.3%, and 96.2%, respectively (P < 0.0001). Nonadherent patients were more likely to be unemployed and to have a greater PRO impairment at baseline (up to -5.3% lower PRO scores, P < 0.0001). During treatment with interferon- or RBV-based regimens, nonadherent patients experienced lower PROs and had larger decrements from their baseline PRO scores. In contrast, there were no significant declines in PRO scores (all P > 0.05) for the small number of patients who were nonadherent to LDV/SOF. In multivariate analysis, being treatment-naive, longer treatment duration, and receiving an interferon- or RBV-containing regimen were associated with a lower likelihood of adherence (all P < 0.003). Better baseline and on-treatment PRO scores were associated with a higher likelihood of adherence to interferon and RBV.The use of interferon and/or RBV, longer duration of treatment, and lower baseline and on-treatment PRO scores were linked to a decreased likelihood of being adherent to interferon + RBV-containing or interferon-free RBV-containing antiviral regimens. Interferon- and RBV-free regimens were associated with excellent adherence.Keywords
This publication has 37 references indexed in Scilit:
- Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature reviewPatient Preference and Adherence, 2013
- Evaluation of Medication Adherence and Quality of Life in Patients With Hepatitis C Virus Receiving Combination TherapyGastroenterology Nursing, 2010
- Psychiatric Problems in Patients Infected with Hepatitis C Before and During Antiviral Treatment with Interferon-Alpha: A ReviewJournal of Psychiatric Practice, 2009
- Fatigue and Health-Related Quality of Life (HRQL) in Chronic Hepatitis C Virus InfectionDigestive Diseases and Sciences, 2007
- Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users?Digestive and Liver Disease, 2006
- Reasons for non‐treatment of hepatitis C in veterans in careJournal of Viral Hepatitis, 2005
- Effectiveness of interferon α-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practiceClinical Gastroenterology and Hepatology, 2004
- Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration.Cleveland Clinic Journal of Medicine, 2004
- The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis CJournal of Hepatology, 2004
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993